Novo Nordisk A/S (LON:0QIU)

Market Cap	196.44B
Revenue (ttm)	35.84B
Net Income (ttm)	12.76B
Shares Out	n/a
EPS (ttm)	2.87
PE Ratio	15.39
Forward PE	16.23
Dividend	1.32 (0.35%)
Ex-Dividend Date	Aug 15, 2025

Volume	842,835
Average Volume	1,375,175
Open	367.60
Previous Close	373.65
Day's Range	366.15 - 381.98
52-Week Range	287.55 - 838.40
Beta	0.24
RSI	54.62
Earnings Date	Nov 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QIU

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK